SRI is conducting preclinical development of treatments for diseases such as tuberculosis, West Nile virus, hepatitis, and biodefense pathogens and toxins.
SRI is identifying candidates for advanced therapies in multiple disease areas by developing compounds from synthetically optimized, natural dietary products.
Lack of sleep can lead to a range of cognitive, attention, and emotional deficits. SRI and its partner have made a thorough study of its effects on the brain.
Novel molecular targets of several cytokines are being evaluated by SRI scientists, with the goal of designing a small-molecule drug to block responses involved in many of these inflammatory diseases.
Predicting individuals' vulnerability to nicotine dependence could identify factors in genes and the environment that help to explain the success or failure of attempts to prevent tobacco use and addiction.
Sleep complaints are common during the transition to menopause, yet we have little understanding of what drives this increase in sleep disturbance and how best to treat it. SRI researchers are investigating sleep quality in women who have begun to go through menopause.
Through a broad range of services for the National Institutes of Health, SRI is accelerating preclinical development of potential therapies for diseases that affect millions of people.
For the National Institute of Mental Health (NIMH), SRI performs preclinical safety and pharmacokinetics studies for brain imaging agents and drugs to treat mental illnesses.
SRI is analyzing the genetics of smoking and related characteristics, using data from a large-scale National Cancer Institute study on smoking cessation.
SRI established the Twin Research Registry as part of its scientific research and efforts to discover more about human behavior. Fraternal and identical twins and multiples of all ages are invited to join the Registry for consideration for research studies.
SRI is studying twins to gain more clinical insight into physiologic response to powerful opioid painkillers. Study results should help to optimize pain relief and minimize adverse effects.
Vitamin A deficiency causes susceptibility — especially in children — to diarrhea-causing infections, which lead to millions of deaths each year. SRI is developing a probiotic that produces the vitamin.
